A Novel 68 Ga‐Labeled 2‐Azabicyclo[3.1.0]Hexane‐3‐Carbonitrile‐Based Fibroblast Activation Protein‐Targeted Tracer for Cancer Imaging With Positron Emission Tomography
Journal of Labelled Compounds and Radiopharmaceuticals · 2025
DOI: 10.1002/jlcr.4143 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Labelled Compounds and Radiopharmaceuticals, 2025. Verfasst von Chao-Cheng Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC, Canada. Hauptthemen laut MEDLINE: Gallium Radioisotopes, Positron-Emission Tomography, Membrane Proteins, Serine Endopeptidases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: CIHR, Canadian Institutes of Health Research.
Abstract (Originalsprache)
Most of the reported small molecule‐based fibroblast activation protein (FAP)‐targeted radioligands are derived from UAMC1110 and contain a 4‐difluoro‐2‐cyanopyrrolidine moiety. In this study, we investigated the effect of replacing the 4‐difluoro‐2‐cyanopyrrolidine moiety of [ 68 Ga]Ga‐FAPI‐04 with 2‐azabicyclo[3.1.0]hexane‐3‐carbonitrile on the in vitro /vivo FAP‐targeting capability. The newly derived 68 Ga‐labeled FAP‐targeted tracer, [ 68 Ga]Ga‐JC02076, was obtained in 43.5 ± 10.4% decay‐corrected radiochemical yield within 33.5 ± 5.8 min ( n = 4). The radiochemical purity and molar activity were 97.2 ± 3.4% and 411.6 ± 232.5 GBq/μmol, respectively. Ga‐JC02076 showed good binding affinity for FAP (IC 50 = 29.7 ± 3.5 nM). Most importantly, [ 68 Ga]Ga‐JC02076 enabled clear visualization of HEK293T:hFAP tumor xenografts in PET images and had good tumor uptake (7.17 ± 2.19 %ID/g) and excellent tumor‐to‐bone (17.3 ± 6.99) and tumor‐to‐muscle (32.3 ± 12.5) uptake ratios at 1 h post‐injection. Our data suggest that N ‐(4‐quinolinoyl)‐Gly‐(2‐azabicyclo[3.1.0]hexane‐3‐carbonitrile) is a promising pharmacophore for the design of FAP‐targeted tracers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC, Canada.
- Department of Molecular Imaging and Therapy, BC Cancer, Vancouver, BC, Canada.
- Department of Radiology, University of British Columbia, Vancouver, BC, Canada.
ORCID-Profile: Kuo-Shyan Lin
Förderung
- CIHR
- Canadian Institutes of Health Research
Zitieren
APA
Chen, C. C., Wang, L., Wong, A. A. W. L., Lau, W. S., Ng, P., Merkens, H., Bénard, F., & Lin, K. S. (2025). A Novel 68 Ga‐Labeled 2‐Azabicyclo[3.1.0]Hexane‐3‐Carbonitrile‐Based Fibroblast Activation Protein‐Targeted Tracer for Cancer Imaging With Positron Emission Tomography. Journal of Labelled Compounds and Radiopharmaceuticals. https://doi.org/10.1002/jlcr.4143
Vancouver
Chen CC, Wang L, Wong AAWL, Lau WS, Ng P, Merkens H, et al. A Novel 68 Ga‐Labeled 2‐Azabicyclo[3.1.0]Hexane‐3‐Carbonitrile‐Based Fibroblast Activation Protein‐Targeted Tracer for Cancer Imaging With Positron Emission Tomography. Journal of Labelled Compounds and Radiopharmaceuticals. 2025. doi:10.1002/jlcr.4143
BibTeX
@article{Chen2025,
author = {Chen, Chao-Cheng and Wang, Lei and Wong, Antonio A W L and Lau, Wing Sum and Ng, Pauline and Merkens, Helen and Bénard, François and Lin, Kuo-Shyan},
title = {A Novel 68 Ga‐Labeled 2‐Azabicyclo[3.1.0]Hexane‐3‐Carbonitrile‐Based Fibroblast Activation Protein‐Targeted Tracer for Cancer Imaging With Positron Emission Tomography},
journal = {Journal of Labelled Compounds and Radiopharmaceuticals},
year = {2025},
doi = {10.1002/jlcr.4143}
}
EUVIMED